PEPG (pepgen.com) Market Value to Book Value Ratio
This daily price chart on the GURU.Markets platform illustrates the price action of PepGen Inc. (PEPG), whose business model relies on RNA therapy for muscle pathologies via the EDO system with a closed patent cycle. PepGen Inc. (PEPG) is implementing advanced drug delivery methods into affected tissues to combat rare genetic disorders. The metric stands at 1.45, while high trial costs and FDA oversight create a defensive barrier against competitors.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PEPG_-_PepGen-Inc._-_Capitalization-to-Book-Value-Ratio "PEPG PepGen Corp Market Capitalization to Book Value Ratio (04/28/2023 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for PepGen Inc. (PEPG)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:PEPG PepGen Inc
PepGen Inc. is a typical biotech startup with a high dependency on clinical trial results. Analyzing the company's current P/B ratio, an investor sees a market premium over the value of net assets. This ratio compares the business's market value with its book value, measuring market expectations regarding future success. For PepGen Inc. (PEPG), this metric reflects the value of intellectual property in the absence of revenue. The trend's stability confirms the adequacy of cash reserve management amid intensive R&D expenditures.
Competitor analysis
Market Capitalization to Book Value Ratio BIIB (Biogen Inc.)|NBIX (neurocrine.com) - Market Value to Equity Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|BHVN (Biohaven Corp) - Market-to-Book Ratio|Market Value to Book Value Ratio Amylyx Pharmaceuticals AMLX|Market Capitalization to Net Assets trevitherapeutics.com|Praxis Precision Medicines, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio AVXL (Anavex)|CeriBell Corp (CBLL) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Prothena PRTA|Market Capitalization to Book Value Ratio ALEC|ANNX - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio OMER|NGNE (Neurogene Inc) - Market-to-Book Ratio|Market Value to Book Value Ratio AC Immune Corp (ACIU)|Capitalization to Book Value Ratio Voyager Corp (VYGR)|Neumora Therapeutics (NMRA) - Market Cap to Net Assets Ratio|Market Value to Book Value scilexholding.com (SCLX)|Market Capitalization to Book Value Ratio TVGN|Alpha Cognition Inc - Market Capitalization to Book Value|Cognition Therapeutics, Inc. (CGTX) - Market Value to Book Value Ratio|IKT - Capitalization to Book Value Ratio|SAVA (Cassava Sciences, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Assertio|COYA: Market Cap to Net Assets Ratio|Market Capitalization to Book Value VTGN|OVID - Market Value to Book Value Ratio|Market Capitalization to Net Assets Acumen Pharmaceuticals, Inc (ABOS)|CRVO: Market Capitalization to Book Value Ratio|Alterity Therapeutics Ltd. - Market-to-Book Ratio|Market Value to Book Value Ratio Clene Nanomedicine|JUNS - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio RLMD (Relmada)|ANVS (Annovis Bio Corporation) - Market Value to Equity Ratio|Market Value to Book Value Ratio Grace Therapeutics Inc (GRCE)|Capitalization to Book Value Ratio fireflyneuro.com|Klotho Neurosciences Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio neurosense-tx.com NRSN|Market Cap to Net Assets Ratio RVPH (Reviva Pharmaceuticals Holdings)|MetaVia Inc. - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NeurAxis, Inc. (NRXS)|HSDT: Market Value to Book Value|Market Value to Book Value Ratio PASG|NEUP (Neuphoria Therapeutics) - Market-to-Book Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp NERV|Market Capitalization to Net Assets Athira Pharma Corp|Addex Therapeutics - Market Capitalization to Book Value Ratio|Market-to-Book Ratio ALZN (alzamend.com)|Cyclerion Therapeutics, Inc. (CYCN) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Protagenic Therapeutics Inc. PTIX|Market Capitalization to Book Value Ratio KTTA|CRGT - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio ATXI|BCLI (brainstorm-cell.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Cara Therapeutics (CARA)|Capitalization to Book Value Ratio Chromocell Therapeutics Corp (CHRO)|Eliem Therapeutics (ELYM) - Market Cap to Net Assets Ratio|Market Value to Book Value intracellulartherapies.com (ITCI)|Market Capitalization to Book Value Ratio LBPH|marinuspharma.com - Market Capitalization to Book Value|NKGen Biotech (NKGN) - Market Value to Book Value Ratio|NRBO - Capitalization to Book Value Ratio|SAGE (Sage Therapeutics, Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Synaptogenix, Inc|TRVN: Market Cap to Net Assets Ratio|Market Capitalization to Book Value VIGL|WENA - Market Value to Book Value Ratio|Market Capitalization to Net Assets Cerevel Therapeutics Inc (CERE)